Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 February 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Development of peanut allergy and protection against peanut ingestion

Separate research teams in this week's New England Journal of Medicine address the development of peanut allergy, and the use of anti-IgE therapy to protect against unintended peanut ingestion.

News image

fiogf49gjkf04

The prevalence of peanut allergy appears to have increased in recent decades.

However, apart from a family history of peanut allergy and the presence of atopy, there are no known risk factors.

In this study, researchers from England used data from a geographically defined cohort of 13,971 preschool children to identify those with a history of peanut allergy. The team also assessed a subgroup that reacted to a double-blind peanut challenge.

The team prospectively collected data on the whole cohort. They then collected information by interview from the parents of children with peanut reactions, and of children from 2 groups of controls.

The controls were randomly selected from the cohort, and from children whose mothers had a history of eczema and who had had eczema themselves in their first 6 months.

Development of peanut allergy was associated with the use of skin preparations containing peanut oil.
New England Journal of Medicine

Overall, 49 children had a history of peanut allergy. This was confirmed by peanut challenge in 23 of 36 children tested.

The research team found no evidence of prenatal sensitization from the maternal diet. They also determined that peanut-specific IgE was not detectable in the cord blood.

They found that peanut allergy was independently associated with intake of soy milk or soy formula (OR 2.6), rash over joints and skin creases (OR 2.6), and oozing, crusted rash (OR 5.2).

In addition, analysis of interview data showed that the use of skin preparations containing peanut oil was an independent factor in the development of peanut allergy (OR 6.8).

Dr Gideon Lack's team concluded, "Sensitization to peanut protein may occur in children through the application of peanut oil to inflamed skin".

"The association with soy protein could arise from cross-sensitization through common epitopes."

"Confirmation of these risk factors in future studies could lead to new strategies to prevent sensitization in infants who are at risk for subsequent peanut allergy."

In the same publication, a further article looks at the effect of anti-IgE therapy in patients with peanut allergy. Peanut-induced anaphylaxis is an IgE-mediated condition that is estimated to affect 1.5 million people. It causes between 50 and 100 deaths per year in the United States.

TNX-901 is a humanized IgG1 monoclonal antibody against IgE. It recognizes and masks an epitope in the CH3 region of IgE responsible for binding to the high-affinity Fcepsilon receptor on mast cells and basophils.

In this study, researchers from the United States conducted a double-blind, randomized, dose-ranging trial in 84 patients with a history of hypersensitivity to peanut.

The team confirmed hypersensitivity in all patients. They then established the threshold dose of encapsulated peanut flour using a double-blind, placebo-controlled oral food challenge.

The researchers randomly assigned patients to receive either TNX-901 (150, 300, or 450 mg) or placebo subcutaneously every 4 weeks for 4 doses.

The patients then underwent a final oral food challenge within 2 to 4 weeks after the fourth dose.

The research team determined a mean baseline threshold of sensitivity of 178 to 436 mg of peanut flour in the various groups.

They found that mean increases in the oral-food-challenge threshold were 710 mg in the placebo group, 913 mg in the 150 mg TNX-901 group, 1650 mg in the 300 mg TNX-901 group, and 2627 mg in the 450 mg TNX-901 group.

The team found that TNX-901 was well tolerated.

Dr Donald Leung's team concluded, "A 450-mg dose of TNX-901…increased the threshold of sensitivity to peanut on oral food challenge from a level equal to approximately half a peanut (178 mg) to one equal to almost 9 peanuts (2805 mg)".

This is "An effect that should translate into protection against most unintended ingestions of peanuts".

New Engl J Med 2003; 348: 977-85, 986-93
17 March 2003

Go to top of page Email this page Email this page to a colleague

 23 February 2017 
Safer interval elective surgery for adults with Crohn's
 23 February 2017 
Quality of care for GERD 
 23 February 2017 
Video games in covert hepatic encephalopathy
 23 February 2017 
Video games in covert hepatic encephalopathy
 22 February 2017 
Confocal laser endomicroscopy for gastric cancer
 22 February 2017 
Predicting response to corticosteroids in severe alcoholic hepatitis
 22 February 2017 
Gluten exposure in celiac disease
 21 February 2017 
Cancer survival in Lynch syndrome 
 21 February 2017 
Motor peripheral nerve injury after colorectal surgery
 21 February 2017 
Anesthetics during outpatient gastroenterology procedures
 20 February 2017 
Advanced neoplasms with low-risk adenomas
 20 February 2017 
Concepts of cirrhotic coagulopathy
 20 February 2017 
Smoking at diagnosis and colon cancer survival
 17 February 2017 
Genetic mutations predict esophageal cancer
 17 February 2017 
Genetic mutations predict esophageal cancer
 17 February 2017 
Anesthesia services during outpatient gastroenterology procedures
 16 February 2017 
Hysterectomy and pelvic floor disorders
 16 February 2017 
Anesthetist-directed sedation in endoscopic procedures
 16 February 2017 
Assisted reproduction in women with IBD 
 15 February 2017 
Metal stents for palliation in malignant biliary obstruction
 15 February 2017 
Hepatocellular carcinoma in the USA
 15 February 2017 
Increasing screening of cirrhosis in hepatocellular carcinoma
 14 February 2017 
Pathologists agreement in the diagnosis of Barrett's
 14 February 2017 
Preventive care in IBD 
 14 February 2017 
Infliximab dose for acute severe ulcerative colitis
 13 February 2017 
Vasoactive drugs for hepatorenal syndrome type 1
 13 February 2017 
Pregnancy outcomes after endoscopy
 13 February 2017 
H. pylori treatment guidelines
 10 February 2017 
Primary ileocecal resection in pediatric Crohn's disease
 10 February 2017 
Non-adherence in end-stage liver disease
 10 February 2017 
Isolated colonic Crohn's disease
 09 February 2017 
Mucosal healing in ulcerative colitis
 09 February 2017 
NAFLD and coronary artery calcium score
 09 February 2017 
Prevalence of Hep D in chronic Hep B infection
 08 February 2017 
Rifaximin for small intestine bacterial overgrowth
 08 February 2017 
Risk prediction of interval cancers from inadequate colonoscopy quality
 08 February 2017 
Meta-analyses in gastroenterology and hepatology journals
 07 February 2017 
Chemoprevention in colon cancer
 07 February 2017 
Untreated hepatocellular carcinoma in the USA
 07 February 2017 
Methotrexate intolerance in pediatric IBD 
 06 February 2017 
Vitamin D levels and risk of relapse in ulcerative colitis
 06 February 2017 
Giardia in the USA
 06 February 2017 
Colorectal cancer risk in serrated polyposis syndrome
 03 February 2017 
Helicobacter and Campylobacter in IBD
 03 February 2017 
Mortality risk in elderly-onset IBD
 03 February 2017 
Management of chronic refractory pouchitis
 02 February 2017 
IBD-related research and publications
 02 February 2017 
TWEAK in IBD
 02 February 2017 
Clostridium difficile and colectomy risk in IBD
 01 February 2017 
Suboptimal bowel preparation in outpatient colonoscopy
 01 February 2017 
Fecal microbiota transplantation
 01 February 2017 
Socio-economic distribution of IBD 
 31 January 2017 
Gastroenterology fellowship
 31 January 2017 
Approach to Lynch syndrome
 31 January 2017 
Fat intake and ulcerative colitis risk
 30 January 2017 
Dietary risk of acute pancreatitis
 30 January 2017 
Care pathway for anemia in IBD 
 30 January 2017 
Mortality in elderly-onset IBD
 27 January 2017 
Therapeutic drug monitoring in IBD 
 27 January 2017 
Cancer mortality in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us